SEC Form 4 · accession 0001140361-18-032462
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony G. Quinn
Officer — Interim CEO · Director
Period of report
Jul 12, 2018
Accepted (ET)
Jul 16, 2018 · 9:04 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 12, 2018 | M | 24,000 | $7.04 | A | 77,927 | D | |
| Common Stock | Jul 12, 2018 | M | 14,866 | $6.31 | A | 92,793 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $7.04 | Jul 12, 2018 | M | 24,000 | D | — | Apr 20, 2027 | Common Stock | 24,000 | 0 | D |
| Director Stock Option (right to buy)F2 | $6.31 | Jul 12, 2018 | M | 14,866 | D | — | Feb 19, 2028 | Common Stock | 14,866 | 163,534 | D |
Explanation of responses
- F1The stock option is fully vested and immediately exercisable.
- F2The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.